CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)	Total	Rpi Finance Trust	Common Stock	Common Stock Rpi Finance Trust	Capital Contributed in Excess of Par	Capital Contributed in Excess of Par Rpi Finance Trust	Treasury Stock	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interest	Convertible preferred stock	Private placement Seattle Genetics, Inc., (“SGEN”)	Private placement Common Stock Seattle Genetics, Inc., (“SGEN”)	Private placement Capital Contributed in Excess of Par Seattle Genetics, Inc., (“SGEN”)	IPO	IPO Common Stock	IPO Capital Contributed in Excess of Par
Beginning balance (in shares) at Jun. 30, 2015			94,546,578
Beginning balance at Jun. 30, 2015	$ (4,524,621)		$ 945,465		$ 305,229,354		$ (458,370)	$ (309,468,004)	$ (161,092)	$ (611,974)
Exercise of stock options (in shares)			1,097,500
Exercise of stock options, net	2,732,962		$ 10,975		2,721,987
Stock based compensation (in shares)			223,220
Stock based compensation	3,371,542		$ 2,232		3,369,310
Other comprehensive income	28,866								28,866
Net loss	(59,135,716)							(59,036,950)		(98,766)
Ending balance at Jun. 30, 2016	(57,526,967)		$ 958,672		311,320,651		(458,370)	(368,504,954)	(132,226)	(710,740)
Ending balance (in shares) at Jun. 30, 2016			95,867,298
Exercise of stock options (in shares)			1,279,354
Exercise of stock options, net	4,290,103		$ 12,794		4,277,309
Stock based compensation (in shares)			197,991
Stock based compensation	3,786,407		$ 1,980		3,784,427
Other comprehensive income	(170,484)								(170,484)
Net loss	(153,266,286)							(153,205,945)		(60,341)
Issuance of preferred stock (in shares)											1,000,000
Issuance of preferred stock, net	121,781,941				121,771,941						$ 10,000
Issuance of common stock (in shares)			10,000,000										3,000,000
Issuance of common stock, net	28,578,473		$ 100,000		28,478,473							$ 14,700,000	$ 30,000	$ 14,670,000
Proceeds of public offering allocated to warrant liability	(6,966,435)				(6,966,435)							$ (14,670,000)		$ (14,670,000)
Ending balance at Jun. 30, 2017	(59,463,248)		$ 1,103,446		462,666,366		(458,370)	(521,710,899)	(302,710)	(771,081)	$ 10,000
Ending balance (in shares) at Jun. 30, 2017			110,344,643								1,000,000
Reclassification of warrant liability to equity	190,368,801				190,368,801
Exercise of common stock warrants (in shares)			18,205,804
Exercise of common stock warrants	78,225,940		$ 182,058		78,043,882
Exercise of stock options (in shares)			585,915
Exercise of stock options, net	2,261,240		$ 5,859		2,255,381
Stock based compensation (in shares)			331,329
Stock based compensation	4,027,009		$ 3,312		4,023,697
Conversion of RSU's for tax withholding payments (in shares)			(169,931)
Conversion of RSU's for tax withholding payments	(1,523,183)		$ (1,699)		(1,521,484)
Other comprehensive income	(50,088)								(50,088)
Net loss	(273,886,970)							(273,836,887)		(50,083)
Issuance of common stock (in shares)				4,373,178												13,225,000
Issuance of common stock, net		$ 67,784,000		$ 43,732		$ 67,740,268									$ 299,466,900	$ 132,250	$ 299,334,650
Conversion of preferred shares (in shares)			23,105,360								(1,000,000)
Conversion of Preferred Shares	0		$ 231,054		(221,054)						$ (10,000)
Issuance of common stock due to debt conversion (in shares)			16,799,861
Issuance of common stock due to debt conversion	92,475,265		$ 167,999		92,307,266
Ending balance at Jun. 30, 2018	$ 399,685,666		$ 1,868,011		$ 1,194,997,773		$ (458,370)	$ (795,547,786)	$ (352,798)	$ (821,164)	$ 0
Ending balance (in shares) at Jun. 30, 2018			186,801,159								0				13,225,000